Top Markets
#1 Official Trump Official Trump +42.55%
#2 Melania Meme Melania Meme +25.21%
#3 Wrapped STX (Velar) Wrapped STX (Velar) +19.59%
#4 Mubarak Mubarak +19.33%
#5 EXOD EXOD +18.93%
#6 Unit Pump Unit Pump +15.99%
#7 Pump.fun Pump.fun +15.99%
#8 Nockchain Nockchain +15.79%
#9 Wrapped POL Wrapped POL +14.85%
#10 POL (ex-MATIC) POL (ex-MATIC) +13.79%
Coin of the day
Official Trump Official Trump
Settings
Language
ENGLISH
Currency
USD
Theme
Aeglea BioTherapeutics, Inc. Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics, Inc.

AGLE
Rank in Stocks #23495
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology firm dedicated... Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating human enzyme therapies for rare metabolic diseases. Their leading candidate, pegzilarginase, a recombinant human Arginase 1, is currently in the pivotal Phase III PEACE trial to assess its safety and effectiveness for treating Arginase 1 deficiency. Furthermore, the company is developing AGLE-177, a polyethylene glycol modified enzyme, which is progressing through Phase I/II clinical trials for homocystinuria. Their early-stage pipeline includes AGLE-325 for cystinuria, along with other ongoing research initiatives. Founded in 2013, the company was initially known as Aeglea BioTherapeutics Holdings, LLC, changing its name to Aeglea BioTherapeutics, Inc. in March 2015. It is based in Austin, Texas.
Share Price
$19.30
Last synced: 2023-12-26
Market Cap
$72.77M
Change (1 day)
6.22%
Change (1 year)
0.00%
Country
US
Trade Aeglea BioTherapeutics, Inc. (AGLE)

Category

Healthcare
Revenue for Aeglea BioTherapeutics, Inc. (AGLE)
Revenue in Aug 2026 TTM: 0
According to Aeglea BioTherapeutics, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Aeglea BioTherapeutics, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH